CHAMPIONS ONCOLOGY, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $7.08 per share for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-27
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-07-31 was $4.90, a 19.80% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-07-31 was $6.11, a 19.29% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-07-31 was $7.57, a 15.98% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-07-31 was $9.01, a 0.78% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2026 was $7.08, a 41.32% increase from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.01, a 17.60% decline from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $6.08, a 15.79% decline from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $7.22, a 23.52% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-04-30 | $7.08 10-K · filed 2026-07-27 | |||||
| 2025-04-30 | $5.01 10-K · filed 2025-07-23 | |||||
| 2025-01-31 | $4.49 10-Q · filed 2025-03-17 | |||||
| 2024-10-31 | $4.26 10-Q · filed 2024-12-16 | |||||
| 2024-07-31 | $4.90 10-Q · filed 2024-09-13 | |||||
| 2024-04-30 | $6.08 10-K · filed 2025-07-23 | |||||
| 2024-01-31 | $6.10 10-Q · filed 2024-03-15 | |||||
| 2023-10-31 | $6.40 10-Q · filed 2023-12-13 | |||||
| 2023-07-31 | $6.11 10-Q · filed 2023-09-13 | |||||
| 2023-04-30 | $7.22 10-K · filed 2024-07-19 | |||||
| 2023-01-31 | $7.25 10-Q · filed 2023-03-16 | |||||
| 2022-10-31 | $7.57 10-Q · filed 2022-12-13 | |||||
| 2022-07-31 | $7.57 10-Q · filed 2022-09-12 | |||||
| 2022-04-30 | $9.44 10-K · filed 2023-07-24 | |||||
| 2022-01-31 | $9.44 10-Q · filed 2022-03-15 | |||||
| 2021-10-31 | $9.01 10-Q · filed 2021-12-13 | |||||
| 2021-07-31 | $9.01 10-Q · filed 2021-09-13 | |||||
| 2021-04-30 | $9.24 10-K · filed 2022-07-22 | |||||
| 2021-01-31 | $9.21 10-Q · filed 2021-03-15 | |||||
| 2020-10-31 | $7.29 10-Q · filed 2020-12-14 | |||||
| 2020-07-31 | $8.94 10-Q · filed 2020-09-14 | |||||
| 2020-04-30 | $5.33 10-K · filed 2021-07-26 | |||||
| 2020-01-31 | $5.29 10-Q · filed 2020-03-16 | |||||
| 2019-10-31 | $5.23 10-Q · filed 2019-12-16 | |||||
| 2019-07-31 | $0.00 10-Q · filed 2019-09-16 | |||||
| 2019-04-30 | $9.86 10-K · filed 2020-07-28 | |||||
| 2019-01-31 | $9.86 10-Q · filed 2019-03-18 | |||||
| 2018-10-31 | $8.55 10-Q · filed 2018-12-17 | |||||
| 2018-07-31 | $7.17 10-Q · filed 2018-09-14 | |||||
| 2018-04-30 | $3.01 10-K · filed 2019-07-29 | |||||
| 2018-01-31 | $2.68 10-Q · filed 2018-03-19 | |||||
| 2017-10-31 | $2.51 10-Q · filed 2017-12-15 | |||||
| 2017-07-31 | $2.51 10-Q · filed 2017-09-14 | |||||
| 2017-04-30 | $1.99 10-K · filed 2018-07-30 | |||||
| 2017-01-31 | $1.99 10-Q · filed 2017-03-17 | |||||
| 2016-10-31 | $1.98 10-Q · filed 2016-12-14 | |||||
| 2016-07-31 | $2.10 10-Q · filed 2016-09-14 | |||||
| 2016-07-21 | $2.10 10-K · filed 2019-07-29 | |||||
| 2016-07-19 | $2.10 10-Q · filed 2017-03-17 | |||||
| 2016-04-30 | $5.33 10-K · filed 2017-07-28 | |||||
| 2016-01-31 | $5.33 10-Q · filed 2016-03-16 | |||||
| 2015-10-31 | $6.98 10-Q · filed 2015-12-15 | |||||
| 2015-07-31 | $6.82 10-Q · filed 2015-09-11 | |||||
| 2015-04-30 | $7.92 10-K · filed 2016-07-29 | $0.66 10-K · filed 2015-07-29 | ||||
| 2015-01-31 | $0.72 10-Q · filed 2015-03-17 | |||||
| 2014-10-31 | $0.72 10-Q · filed 2014-12-15 | |||||
| 2014-07-31 | $1.01 10-Q · filed 2014-09-12 | |||||
| 2014-04-30 | $1.23 10-K · filed 2015-07-29 | |||||
| 2014-01-31 | $1.23 10-Q · filed 2014-03-14 | |||||
| 2013-10-31 | $1.18 10-Q · filed 2013-12-13 | |||||
| 2013-07-31 | $0.53 10-Q · filed 2013-09-13 | |||||
| 2013-04-30 | $0.41 10-K · filed 2014-07-28 | |||||
| 2013-01-31 | $0.41 10-Q · filed 2013-03-13 | |||||
| 2012-10-31 | $0.54 10-Q · filed 2012-12-13 | |||||
| 2012-07-31 | $0.57 10-Q · filed 2012-09-12 | |||||
| 2012-04-30 | $0.77 10-K · filed 2013-07-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |